8-K - Allarity Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Allarity Therapeutics, Inc. announced the closing of a $20 million non-convertible debt financing with Streeterville Capital on March 6, 2026. The proceeds are expected to extend the Company's cash runway into the summer of 2028 and fund completion of the Phase 2 ovarian cancer trial for stenoparib, acceleration toward pivotal trial, FDA approval, and commercialization.

Key Takeaways

1Closed $20 million non-convertible debt financing with Streeterville Capital on March 6, 2026

2Issued two promissory notes: $10,930,000 unsecured and $10,000,000 secured, providing approximately $20 million in net proceeds

3Financing extends cash runway into summer of 2028

4Proceeds to fund Phase 2 ovarian cancer trial completion, FDA meeting preparation, companion diagnostic strategy, and pivotal development of stenoparib

5Stenoparib is a dual PARP and WNT pathway inhibitor in Phase 2 trials for platinum-resistant ovarian cancer patients

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Matters. On March 6, 2026, Allarity Therapeutics, Inc. (the “Company”) announced the closing of a $20 million non-convertible debt financing with Streeter

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated March 6, 2026. 104 Cover Page Interactive Data File (embed

Exhibits Only

Source Document

Transaction Details

Debt / Financing

Instrument: non-convertible promissory notes
Principal: $20 million (net proceeds approximately $20 million)
Use of Proceeds: primarily to support acceleration of stenoparib toward pivotal development, FDA approval and commercialization, including completion of Phase 2 ovarian cancer trial, FDA meeting preparation, companion diagnostic strategy, and pivotal development

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED MARCH 6, 2026